Analyst Ratings For Biogen (NASDAQ:BIIB)
Today, Royal Bank of Canada lowered its price target on Biogen (NASDAQ:BIIB) to $236.00 per share.
There are 21 Hold Ratings, 8 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on Biogen (NASDAQ:BIIB) is Hold with a consensus target price of $300.8135 per share, a potential 36.70% upside.
Some recent analyst ratings include
- 3/22/2019-Biogen (NASDAQ:BIIB) had its Hold rating reiterated by Barclays with a $250.00 price target
- 3/22/2019-Biogen (NASDAQ:BIIB) gets downgraded to Neutral by UBS Group with a price target of $242.00
- On 3/18/2019 Robert W Pangia, Director, sold 6,114 with an average share price of $328.55 per share and the total transaction amounting to $2,008,754.70.
- On 2/1/2019 Alexander J Denner, Director, bought 7,000 with an average share price of $328.45 per share and the total transaction amounting to $2,299,150.00.
- On 1/30/2019 Alexander J Denner, Director, bought 30,000 with an average share price of $324.86 per share and the total transaction amounting to $9,745,800.00.
- On 9/26/2018 Michael D Ehlers, EVP, sold 1,000 with an average share price of $350.00 per share and the total transaction amounting to $350,000.00.
- On 4/25/2018 Alexander J Denner, Director, bought 48,000 with an average share price of $269.91 per share and the total transaction amounting to $12,955,680.00.
- On 2/27/2018 Alfred Sandrock, EVP, sold 259 with an average share price of $290.83 per share and the total transaction amounting to $75,324.97.
- On 2/20/2018 Alfred Sandrock, EVP, sold 743 with an average share price of $292.00 per share and the total transaction amounting to $216,956.00.
About Biogen (NASDAQ:BIIB)
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Recent Trading Activity for Biogen (NASDAQ:BIIB)
Shares of Biogen closed the previous trading session at 220,23 up +3,52 1,62 % with 220.02 shares trading hands.